Samsung Bioepis will distribute an interim cash dividend of 104.3 billion won to its wholly-owned holding company, Samsung Epise Holdings.
On November 11, Samsung Bioepis' board of directors resolved to pay a total of 104.3 billion won in cash dividends to Samsung Epise Holdings, as announced on November 12. The dividend per share is set at 5,043 won. The record date for the dividend is December 4, and the payment date is December 18. The funds will be used to enhance the financial flexibility of Samsung Epise Holdings and to support its operational activities.
The company stated, "This is a routine capital allocation process based on the profit generation of Samsung Bioepis, conducted in accordance with the Commercial Act and our articles of incorporation." It added, "Utilizing the dividends from subsidiaries as a primary resource for Samsung Epise Holdings has been disclosed since the announcement of the corporate split last May." Furthermore, it noted that Samsung Epise Holdings is exploring various uses to ensure stable operations and future growth in the fields of new drugs and biosimilars under the holding company structure.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.